Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep1051 | Thyroid (non-cancer) | ECE2015

Seaweed derived gaseous iodine: a source of iodine intake in coastal communities?

Smyth Peter , Burns Robert , Casey Michael , Andersson Maria , Mullan Karen , O'Dowd Colin

This communication tests the hypothesis that iodine (I2) gas or iodine oxides released from seaweeds previously shown to enhance atmospheric iodine adjacent to seaweed hotspots, may through being inspired by respiration, supply a significant fraction of daily iodine requirements. This could assume importance in a country such as Ireland where iodised salt availability is <5%. Iodine intake was assessed by measuring urinary iodine (UI) excretion using a dry ashing technique...

ea0099p581 | Thyroid | ECE2024

Thyroid function might decrease after adjuvant chemotherapy in postmenopausal women with early breast cancer

Marina Djordje , Buch-Larsen Kristian , Gillberg Linn , Andersen Mads , Andersson Michael , Krogh Rasmussen AEse , Schwarz Peter

Objective: Adjuvant chemotherapy is often indicated in patients diagnosed with early breast cancer. Weight gain is one of the observed side effects of both chemotherapy and other cancer treatments, however, the mechanism is not well-described. In this study, we aimed to assess thyroid function before- and after the course of chemotherapy for early breast cancer.Methods: This study is a 5-year prospective cohort study of patients diagnosed with early brea...

ea0099ep333 | Calcium and Bone | ECE2024

Bone mineral density in women with breast cancer receiving adjuvant aromatase inhibitors and anti-resorptive treatment – healthy living after breast cancer

Jansen Rasmus , Marina Djordje , Diedrichsen Marstrand Simone , Andersson Michael , Nielsen August , Buch Larsen Kristian , Schwarz Peter

Introduction: Aromatase inhibitors, such as Letrozole or Exemestane, are often used as adjuvant treatment for post-menopausal breast cancer. However, they are known to reduce bone mineral density (BMD). Furthermore, breast cancer patients often undergo chemotherapy with drugs associated to BMD loss by themselves. Therefore, patients treated for breast cancer are subject to a considerable risk of BMD loss, and to alleviate this the treatments are normally combined with an anti-...

ea0099ep506 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Post-absorptive and post-prandial glucose and fat metabolism in post-menopausal women with breast cancer after chemotherapy compared to healthy controls

Buch-Larsen Kristian , Marstrand Simone , Marina Djordje , Gilberg Linn , Andersson Michael , Hall Gerrit , Schwarz Peter

Background: Breast cancer survivors are a growing population due to improved treatment. It is known that postmenopausal women treated for breast cancer may experience weight gain and increased insulin resistance, but detailed knowledge on how chemotherapy impact metabolic and endocrine mechanisms remain unknown. Objective: We performed a thorough, preliminary study to elucidate the differing mechanisms of post-prandial absorption and metabolism in postme...

ea0099ep542 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Effect of chemotherapy on glucose metabolism in breast cancer patients

Diedrichsen Marstrand Simone , Marina Djordje , Mendez Valdemar , Andersson Michael , Buch-Larsen Kristian , Schwarz Peter

Background: Observational studies indicate that breast cancer survivors more often are diagnosed with type 2 diabetes mellitus (T2DM) up to several years after treatment completion. As the population of breast cancer survivors increase due to improved diagnostic and treatment methods the importance of understanding possible long-term side effects of the treatment such as T2DM becomes more central. It is reported that women receiving adjuvant chemotherapy experience weight gain...